Will the results be positive?
The market price for YES is 0.48996028. My intrinsic forecast suggests a 40% chance of a positive outcome, which is slightly below the market-implied probability. Given the portfolio has $15716.928 in cash and a max buy... Steady-state cap reduced request to $314.34.
Intrinsic success probability (35%) is significantly lower than the market's implied probability (49.5%), offering a favorable edge. Buying NO shares capitalizes on the negative trial completion gap and the historical...
Intrinsic YES probability (38%) is below market price (~49.5%), creating a pricing gap favoring NO. With no position and cash available, buying NO offers positive expected value. Using full maxBuyUsd to size the trade.
At 49.5%, the market wildly underprices success. CBL-514 met endpoints in 10 prior trials. Phase 2a Dercum's data showed 64% of lipomas shrank >50%. A placebo trial with 5 doses is highly likely to win.
Intrinsic 32% YES vs market 50% (yesPrice 0.50); NO undervalued by ~18pp. Execution risks justify edge. Max buy per cap despite moderate confidence.
